Cite
HARVARD Citation
Du, J. et al. (2022). CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status. American journal of hematology. 97 (7), pp. 933-941. [Online].